Meeting
2022 ASCO Annual Meeting
Evaluation of tumor responses and overall survival in patients with recurrent glioblastoma (GBM) from a phase IIa trial of a CMV vaccine immunotherapeutic candidate (VBI-1901).
Authors
Patrick Y. Wen
Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA
Patrick Y. Wen , David A. Reardon , Deborah Anne Forst , Eudocia Quant Lee , Brittany Haas , Teresa Daoud , Tamara Berthoud , Francisco Diaz-Mitoma , David E Anderson , Andrew B. Lassman , Fabio Massaiti Iwamoto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT03382977
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2014)
DOI
10.1200/JCO.2022.40.16_suppl.2014
Abstract #
2014
Poster Bd #
352
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Interim results of a phase I/IIa trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM).
First Author: Andrew B. Lassman
Poster
2017 ASCO Annual Meeting
Immunological targeting of CD133 in recurrent glioblastoma: A multi-center phase I translational and clinical study of autologous CD133 dendritic cell immunotherapy.
First Author: Jeremy David Rudnick
Poster
2023 ASCO Annual Meeting
Lisavanbulin in patients with recurrent glioblastoma: Phase 2a results and a consolidated analysis of response-predictive biomarkers.
First Author: Juanita Suzanne Lopez
Poster
2023 ASCO Annual Meeting
Efficacy and safety study of neoadjuvant efineptakin alfa (NT-I7) and pembrolizumab in recurrent glioblastoma.
First Author: Mason Webb